<DOC>
	<DOCNO>NCT00203307</DOCNO>
	<brief_summary>Olanzapine ( o-lan-zah-peen ) medication approve Food Drug Administration ( FDA ) treatment patient schizophrenia and/ bipolar disorder . The trade name drug ZyprexaÂ® . Olanzapine approve FDA prevention migraine experimental purpose research study . The Jefferson Headache Center Thomas Jefferson University develop clinical study evaluate safety effectiveness Olanzapine prevent migraine headache .</brief_summary>
	<brief_title>A Research Study Examining Use Olanzapine Prevention Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subjects male female age 18 65 , inclusive Subjects history migraine without aura define IHS criterion , least one year prior screening Subjects experience 3 10 migraine attack per month , three month precede screen Subjects 15 headache day per month Subjects stable dose ( clinically significant change ) daily medication , indication , 28 day prior screen duration trial . Women use , agree use duration study , medically acceptable form contraception ( determined investigator ) , female childbearing potential . Subjects able understand comply study requirement Subjects provide write informed consent prior study procedure perform . Women pregnant lactating Subjects abnormal ECG , investigator opinion , would expose increase risk adverse event interfere study drug and/or analysis efficacy/tolerability ( subject QTC interval great 450ms exclude ) Subjects currently take , take within thirty day prior screen , neuroleptic &gt; 1 day per week ( Geodon , Zyprexa , Compazine , Phenergan , Seroquel drug class ) Subjects currently take take within 4weeks prior screen medication prevention migraine Subjects fail two adequate trial migraine prophylaxis , determine investigator Subjects experience significant orthostatic hypotension , determine investigator Subjects , investigator opinion , history evidence medical condition would expose increase risk significant adverse event would interfere assessment efficacy tolerability trial Subjects , investigator opinion , history evidence psychiatric condition would expose increase risk significant adverse event would interfere assessment efficacy tolerability trial . Subjects participate investigational drug trial 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>